Sage Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sage Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Hold	472	–	–	0.09%	135
2026 Q1	$211K	Hold	472	–	–	0.1%	147
2025 Q4	$214K	Buy	+472	New	+$203K	0.1%	144
2025 Q3	–	Sell	-472	Closed	-$210K	–	164
2025 Q2	$210K	Hold	472	–	–	0.1%	143
2025 Q1	$229K	Buy	+472	New	+$220K	0.12%	128
2024 Q4	–	Sell	-472	Closed	-$220K	–	163
2024 Q3	$220K	Hold	472	–	–	0.11%	138
2024 Q2	$221K	Buy	+472	New	+$205K	0.12%	129

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Sage Capital Management's VRTX Position: Q2 2026 in Review

Sage Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 472 shares worth $234K. The position accounts for 0.09% of the portfolio, ranked #135.

Sage Capital Management first reported a position in VRTX in Q2 2024 and has held it in 7 quarters since. 325 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Sage Capital Management held 472 shares of Vertex Pharmaceuticals worth $234K as of Q2 2026.
Sage Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.09% of Sage Capital Management's portfolio in Q2 2026, its #135 holding.
Sage Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
325 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sage Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.